

S5 Table. Univariate analysis of prognostic factors in ypN0 patients (n=314)

Variable	No. of patients (%)	5-Year LRRFS (%)	p-value	5-Year DFS (%)	p-value	5-Year OS (%)	p-value
Age (yr)			0.27		0.26		0.36
< 40	255 (81.2)	97.9		93.4		98.0	
≥ 40	059 (18.8)	94.9		87.8		94.5	
Histologic grade			0.61		0.06		0.04 ^{a)}
I-II	163 (51.9)	98.1		95.6		99.4	
III	151 (48.1)	96.7		88.9		95.1	
Molecular subtype			< 0.001 ^{a)}		<0.001 ^{a)}		< 0.001 ^{a)}
Luminal HER2(-)	091 (29.0)	98.9		96.5		98.9	
HER2(+)	165 (52.5)	100		95.5		100	
Triple-negative	058 (18.5)	87.2		77.1		87.4	
Ki-67 (%)			0.01 ^{a)}		0.01 ^{a)}		0.13
< 15	136 (43.3)	100		95.9		98.4	
≥ 15	178 (56.7)	95.4		89.7		96.5	
Resection margin status			0.16		0.78		0.18
Negative	304 (96.8)	97.6		92.5		97.6	
Close	010 (3.2)	90.0		90.0		90.0	
Axillary dissection			0.68		0.23		0.07
SLNB	160 (51.0)	96.7		94.8		98.8	
ALND	154 (49.0)	98.0		90.0		96.0	
Lymphovascular invasion			0.14		0.004		0.03 ^{a)}
Absent	267 (85.0)	98.0		94.2		98.5	
Present	047 (15.0)	93.5		82.5		91.1	
Clinical T category			0.71		0.28		0.97
cT1-2	188 (59.9)	96.7		93.8		97.7	
cT3-4	126 (40.1)	98.4		90.2		96.8	
Clinical N category			0.76		0.87		0.63
cN0-1	151 (48.1)	97.8		92.4		97.2	
cN2-3	163 (51.9)	96.9		92.4		97.5	
ypT category			0.12		0.01 ^{a)}		0.005 ^{a)}

ypT0-is	245 (78.0)	97.9		94.4		98.7
ypT1-4	069 (22.0)	95.6		85.1		92.4
Radiation therapy			0.24		0.83	0.81
No	057 (18.2)	94.2		92.5		96.5
Yes	257 (81.9)	98.0		92.3		97.6

ALND, axillary lymph node dissection; DFS, disease-free survival; HER2, human epidermal growth factor receptor; LRRFS, locoregional recurrence-free survival; OS, overall survival; SLNB, sentinel lymph node biopsy. ^{a)}Significant p-value.